SERG-ONE - Optimising PD Therapy
Research type
Research Study
Full title
SERG-ONE - an AI-powered, Mechanomyography (MMG) Sensor Platform to optimise therapy for Parkinson's Disease
IRAS ID
347612
Contact name
Christos Kapatos
Contact email
Sponsor organisation
SERG Technologies
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Parkinson’s Disease (PD) is a progressive neurological condition that affects movement and causes a range of motor and non-motor symptoms, such as tremors, stiffness and anxiety. Effective management of PD includes medication and, in some cases, deep brain stimulation (DBS). However, symptom variability remains a significant challenge, and understanding these fluctuations is important for improving care. Also, access to specialists services varies widely across the UK. An objective therapy optimisation system would empower clinicians to deliver the most out of available treatments to a wider population.
This study aims to explore how motor and non-motor symptoms of PD vary under different treatment conditions and in daily life. The research will involve two groups of participants: one managed with medication and the other also receiving DBS therapy.
Participants will first attend a clinical session where their symptoms will be assessed in controlled conditions. Depending on their treatment group, they will either undergo a Levodopa Challenge (a detailed evaluation of their response to medication) or a DBS Challenge (where symptoms are assessed with the stimulator turned on and off). These assessments will help us understand how treatments affect symptoms.
Participants will then wear a small wearable device at home for two weeks to monitor their symptoms during daily activities. They will also complete a simple symptom diary on a few days during this period to provide additional insights.
By combining clinical and at-home data, this study seeks to better understand symptom patterns and test whether wearable devices can reliably track symptoms and medication states in at-home. The aim is to enable medication efficacy assessments which could inform treatment optimisation for Parkinson's.
REC name
Wales REC 5
REC reference
25/WA/0083
Date of REC Opinion
2 May 2025
REC opinion
Further Information Favourable Opinion